InterStim Micro System
First Patient Implanted in ELITE Study of InterStim Micro System
The Evaluation of InterStim Micro System Performance and Safety (ELITE) study will enroll 160 subjects across 40 sites in the United States (and territories), Europe, Australia and Canada. Endpoints include patient-reported outcomes, disease-specific quality of life questionnaires, and symptom diaries. Patients will be followed for two years.
Medtronic Begins Post-Market, Real-World Study of the InterStim™ Micro System
“SNM therapy is already proven to be safe and effective, but we expect the ELITE study to definitively reinforce established SNM evidence in patients implanted with the new InterStim Micro system,” said Victor Nitti, M.D., the Shlomo Raz Chair in urology, professor of urology and obstetrics and gynecology, and chief and fellowship director of Female Pelvic Medicine and Reconstructive Surgery at the David Geffen School of Medicine at UCLA.
